These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


343 related items for PubMed ID: 12672186

  • 1. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis.
    Gonzalez-Alvaro I, Carmona L, Balsa A, Sanmarti R, Belmonte MA, Tena X, EMECAR Study Group.
    J Rheumatol; 2003 Apr; 30(4):697-704. PubMed ID: 12672186
    [Abstract] [Full Text] [Related]

  • 2. The methotrexate therapeutic response in rheumatoid arthritis.
    Ortendahl M, Holmes T, Schettler JD, Fries JF.
    J Rheumatol; 2002 Oct; 29(10):2084-91. PubMed ID: 12375316
    [Abstract] [Full Text] [Related]

  • 3. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H, Nicola PJ, Crowson CS, O'Fallon WM, Gabriel SE.
    J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
    [Abstract] [Full Text] [Related]

  • 4. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R, Schleusser B, Herborn G, Karger T.
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [Abstract] [Full Text] [Related]

  • 5. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis.
    Verschueren P, Esselens G, Westhovens R.
    Rheumatology (Oxford); 2008 Jan; 47(1):59-64. PubMed ID: 18039681
    [Abstract] [Full Text] [Related]

  • 6. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
    Sokka T, Pincus T.
    J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
    [Abstract] [Full Text] [Related]

  • 7. Prescription rheumatology practices among Mexican specialists.
    Goycochea-Robles MV, Arce-Salinas CA, Guzmán-Vázquez S, Cardiel-Ríos MH.
    Arch Med Res; 2007 Apr; 38(3):354-9. PubMed ID: 17350489
    [Abstract] [Full Text] [Related]

  • 8. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
    Pease C, Pope JE, Truong D, Bombardier C, Widdifield J, Thorne JC, Paul Haraoui B, Psaradellis E, Sampalis J, Bonner A.
    Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
    [Abstract] [Full Text] [Related]

  • 9. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.
    Hurst S, Kallan MJ, Wolfe FJ, Fries JF, Albert DA.
    J Rheumatol; 2002 Aug; 29(8):1639-45. PubMed ID: 12180722
    [Abstract] [Full Text] [Related]

  • 10. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Järvenpää S, Leirisalo-Repo M, Hakala M, Puolakka K, Julkunen H, Luosujärvi R, Möttönen T, FIN-RACo Trial Group.
    Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
    [Abstract] [Full Text] [Related]

  • 11. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
    Weaver AL, Lautzenheiser RL, Schiff MH, Gibofsky A, Perruquet JL, Luetkemeyer J, Paulus HE, Xia HA, Leff JA, RADIUS Investigators.
    Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic strategies in rheumatoid arthritis over a 40-year period.
    Kremers HM, Nicola P, Crowson CS, O'Fallon WM, Gabriel SE.
    J Rheumatol; 2004 Dec; 31(12):2366-73. PubMed ID: 15570636
    [Abstract] [Full Text] [Related]

  • 13. Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice.
    Wluka A, Buchbinder R, Mylvaganam A, Hall S, Harkness A, Lewis D, Littlejohn GO, Miller MH, Ryan PF.
    J Rheumatol; 2000 Aug; 27(8):1864-71. PubMed ID: 10955325
    [Abstract] [Full Text] [Related]

  • 14. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
    Gibofsky A, Palmer WR, Goldman JA, Lautzenheiser RL, Markenson JA, Weaver A, Schiff MH, Keystone EC, Paulus HE, Harrison MJ, Whitmore JB, Leff JA.
    Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
    [Abstract] [Full Text] [Related]

  • 15. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [Abstract] [Full Text] [Related]

  • 16. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial.
    Le Loët X, Nordström D, Rodriguez M, Rubbert A, Sarzi-Puttini P, Wouters JM, Woolley JM, Wright N, Lawrence C, Appleton B.
    J Rheumatol; 2008 Aug; 35(8):1538-44. PubMed ID: 18634163
    [Abstract] [Full Text] [Related]

  • 17. Practice variation in the treatment of rheumatoid arthritis among German rheumatologists.
    Zink A, Listing J, Ziemer S, Zeidler H, German Collaborative Arthritis Centres.
    J Rheumatol; 2001 Oct; 28(10):2201-8. PubMed ID: 11669156
    [Abstract] [Full Text] [Related]

  • 18. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG.
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [Abstract] [Full Text] [Related]

  • 19. Performance of a rheumatoid arthritis records-based index of severity.
    Ting G, Schneeweiss S, Katz JN, Weinblatt ME, Cabral D, Scranton RE, Solomon DH.
    J Rheumatol; 2005 Sep; 32(9):1679-87. PubMed ID: 16142860
    [Abstract] [Full Text] [Related]

  • 20. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
    Fautrel B, Guillemin F, Meyer O, de Bandt M, Berthelot JM, Flipo RM, Lioté F, Maillefert JF, Wendling D, Saraux A, Combe B, Le Loët X, Stratégies Thérapeutiques dans La Polyarthrite RhumatoIde Working Group, Club Rhumatismes et Inflammation, French Society of Rheumatology.
    Arthritis Rheum; 2009 Apr 15; 61(4):425-34. PubMed ID: 19333993
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 18.